{"editorial":{"content_id":"165894f4-c696-4c59-bca9-43a38465105e","slug":"anvisa-20261016-1067a6","content_type":"news","title":"Anvisa 9月30日起启用蓝黄处方电子签发","summary":"巴西国家卫生监督局（Anvisa）自9月30日起允许管制药品的蓝色和黄色处方以电子形式签发，纸质处方仍继续有效。","body":"巴西国家卫生监督局（Anvisa）下属的国家处方控制系统（SNCR）进入新阶段，自9月30日起，管制药品的蓝色和黄色处方可电子签发。该变更允许患者以数字形式获得 A1、A2、A3、B1 和 B2 类药品的处方，无需打印即可在药房出示。\n\n按照新流程，药房调剂时须查询 SNCR、验证处方编号并登记使用，系统核销后编号不可重复使用。Anvisa 表示，这一机制扩大了可追溯性，但不取消此类药品适用的卫生要求，有效期、身份识别、签名和调剂规则均予保留。\n\n电子签发不改变处方有效期，规则与纸质文件相同。数字处方的签发日期对应电子签名日期，患者应保存收到的文件并核对信息是否正确。\n\n并非所有药房都已准备好运行新流程，患者可能需要寻找已启用的药房。此外，纸质处方并未被取消，两种格式继续有效，由具备资质的专业人员选择签发方式并提供给患者。\n\n黄色处方即 A 类通知，用于 A1、A2、A3 类药品，包括麻醉品和需特殊管制的精神药物；蓝色处方即 B 类通知，涵盖 B1、B2 类药品，如部分抗焦虑药和镇静剂。法规还规定了对全身用维A酸类和沙利度胺的电子通知，并为需特殊管制的处方及药房须留存的处方建立集中编号系统。\n\nAfya 医疗总监 Ronaldo Gismondi 表示，数字化在不放弃现有管制药品安全机制的前提下提高了患者便利性，并称数字处方减少了官僚环节，可能有助于患者获得治疗。","why_it_matters":null,"cbi_observation":null,"direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["政策","合规","行业趋势","br-health"],"content_level":"编辑整理","event_type":"政策法规","audience_tags":[],"event_location":null,"verification_status":"unverified","published_at":"2026-10-16T17:03:14.681Z","display_date":"2026-10-16","source_published_at":null,"source_url":"https://panoramafarmaceutico.com.br/anvisa-libera-receitas-azul-e-amarela-em-formato-eletronico/","source_name":"Panorama Farmacêutico","source_language":"pt","author_name":"编辑部","risk_level":"medium","risk_flags":[],"opportunity_flags":[],"trend_signals":[]},"intelligence":null,"meta":{"canonical_url":"https://chinabrazilinsight.com/news/anvisa-20261016-1067a6","api_url":"https://chinabrazilinsight.com/api/public/content/anvisa-20261016-1067a6","markdown_url":"https://chinabrazilinsight.com/api/public/content/anvisa-20261016-1067a6?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/anvisa-20261016-1067a6?view=json","last_updated":"2026-10-16T17:03:41.705Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}